A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumours.

Trial Profile

A Phase 1, Multi-center, Open-label, Dose-escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of EP-100 Given Intravenously 3 Out of 4 Weeks in Subjects With Advanced Solid Tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 May 2014

At a glance

  • Drugs EP 100 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Esperance Pharmaceuticals
  • Most Recent Events

    • 04 Jun 2012 Results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) and in an Esperance Pharmaceuticals media release.
    • 03 Apr 2012 Results will be reported at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2012, according to an Esperance Pharmaceuticals media release.
    • 31 Mar 2012 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top